Status
Active, not recruiting
Phase
Phase 4
Enrollment
60
Locations
1
Results
Not posted
Publications
1
Study summary
The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium. To reduce the amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation activity.
Interventions
DRUG
Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
OTHER
The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
DRUG
The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
PROCEDURE
The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
Timeline
First posted
Feb 27, 2019
Study start
Mar 18, 2019
Primary completion
Dec 31, 2026
Study completion
Dec 31, 2026
Results posted
Not reported
Registry updated
May 1, 2026
Outcomes
Change in size of Left Atrial Epicardial Adipose Tissue (LAEAT)
Time frame · Baseline, 3 months (prior to ablation)
As assessed via multi detector cardiac computer tomography (MD-CT)
Change in size of Epicardial Adipose Tissue (EAT) thickness
Time frame · Baseline, 3 months (prior to ablation), 1 year post-ablation
As assessed via echocardiography
Change in atrial function
Time frame · Baseline, 1 year post ablation
As assessed via echocardiography
Change in atrial size
Time frame · Baseline, 1 year post ablation
As assessed via echocardiography
Change in C-Reactive Protein (CRP) value
Time frame · Baseline, 1 year post ablation
Serial changes in biomarkers of inflammation
Change in Interleukin-6 (IL-6)
Time frame · Baseline, 1 year post ablation
Serial changes in biomarkers of inflammation
Correlation of CRP expression in blood from left atrium to peripheral plasma
Time frame · During the catheter ablation procedure
At the same time point, blood will be collected directly from left atrium and peripheral vessel during the ablation procedure and compared
Correlation of IL-6 expression in blood from left atrium to peripheral plasma
Time frame · During the catheter ablation procedure
At the same time point blood, will be collected directly from left atrium and the peripheral vessel during the ablation procedure and compared
Correlation of plasminogen activator inhibitor (PAI-1), matrix metalloproteinase-2 (MMP2), Tissue inhibitor of metalloproteinase 2 (TIMP-2)
Time frame · During the catheter ablation procedure
At the same time point, blood will be collected directly from left atrium and the peripheral vessel during the ablation procedure and compared
Correlation of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)
Time frame · During the catheter ablation procedure
At the same time point, blood will be collected directly from left atrium and the peripheral vessel during the ablation procedure and compared
Eligibility
Inclusion Criteria: * Male and female, age 18 or older * Persistent AF defined as continuous AF sustained beyond 7 days (or AF with the decision to cardiovert before 7 days of enrollment or Paroxysmal AF defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days * BMI ≥27 kg/m2 * Patient wishes to undergo a catheter ablation procedure for the treatment of atrial fibrillation * Receiving follow-up care at the University of Miami Exclusion Criteria: * Inability to sign an informed consent * Patients with longstanding persistent atrial fibrillation of more than 3 years * Prior ablation for atrial fibrillation * Patients not appropriate candidates for catheter ablation such as those with AF due to acute or chronic precipitating medical conditions, for example, hypothyroidism and hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial thrombus, class IV heart failure) * Patients with a life expectancy \<1 year * Patients with a serious medical condition (for example, recent cancer with chemotherapy or radiation therapy within 4 weeks before entering the study) who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Known contraindications to Liraglutide, such as the previous history of pancreatitis or medullary thyroid carcinoma * Personal or family history of multiple endocrine neoplasias * Known serious hypersensitivity reaction to Liraglutide * Patients using, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other GLP-1 analogs, or DPP4 inhibitors * Type 1 diabetes, defined by American Diabetes Association criteria, history of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to pancreatitis or pancreatectomy * Poorly controlled type 2 diabetes with HbA1c \> 10% * Pregnant women * Women who are breast-feeding or intend to become pregnant
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
University of Miami
Miami, Florida, United States
Related trials
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
4Moving Biotech · Knee Osteoarthritis · Synovitis of Knee
Phase 2
Active, not recruiting
129
2026-07
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Type 2 Diabetes Mellitus · Mild Cognitive Impairment
Not applicable
Completed
396
2026-07
Phase 1
Recruiting
71
2026-07
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
78
2026-07
West China Hospital · Alzheimer Disease · Diabetes Mellitus Type 2
Not applicable
Completed
213,891
2026-07
Indiana University · Obesity
Not applicable
Enrolling by invitation
125,000
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.